{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:10:57Z","timestamp":1770279057638,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,20]]},"DOI":"10.7759\/cureus.49121","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:10:20Z","timestamp":1700503820000},"source":"Crossref","is-referenced-by-count":6,"title":["Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments"],"prefix":"10.7759","author":[{"given":"Yasha N","family":"Suryawanshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh  A","family":"Warbhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01565-5","article-title":"Familial hypercholesterolemia: global burden and approaches","volume":"23","author":"Tokgozoglu L","year":"2021","unstructured":"Tokgozoglu L, Kayikcioglu M. Familial hypercholesterolemia: global burden and approaches. Curr Cardiol Rep. 2021, 23:151. 10.1007\/s11886-021-01565-5","journal-title":"Curr Cardiol Rep"},{"key":"ref2","unstructured":"National Human Genome Research Institute. About familial hypercholesterolemia. (2013). Accessed: July 23, 2023: https:\/\/www.genome.gov\/Genetic-Disorders\/Familial-Hypercholesterolemia."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2015.01.001","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie VE","year":"2015","unstructured":"Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin. 2015, 33:169-79. 10.1016\/j.ccl.2015.01.001","journal-title":"Cardiol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2069.132478","article-title":"Familial hypercholesterolemia: a review","volume":"7","author":"Varghese MJ","year":"2014","unstructured":"Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol. 2014, 7:107-17. 10.4103\/0974-2069.132478","journal-title":"Ann Pediatr Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113426","article-title":"Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease","volume":"19","author":"Benito-Vicente A","year":"2018","unstructured":"Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 2018, 19:3426. 10.3390\/ijms19113426","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen LE","year":"2017","unstructured":"Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, Tu JV. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017, 7:e016461. 10.1136\/bmjopen-2017-016461","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7556\/jaoa.2014.023","article-title":"Preventing early cardiovascular death in patients with familial hypercholesterolemia","volume":"114","author":"Repas TB","year":"2014","unstructured":"Repas TB, Tanner JR. Preventing early cardiovascular death in patients with familial hypercholesterolemia. J Am Osteopath Assoc. 2014, 114:99-108. 10.7556\/jaoa.2014.023","journal-title":"J Am Osteopath Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.71.3.788","article-title":"Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity","volume":"71","author":"Brown MS","year":"1974","unstructured":"Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci U S A. 1974, 71:788-92. 10.1073\/pnas.71.3.788","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14234-1","article-title":"Dyslipidaemia","volume":"12","author":"Durrington P","year":"2003","unstructured":"Durrington P. Dyslipidaemia. Lancet. 2003, 12:717-31. 10.1016\/S0140-6736(03)14234-1","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"6","author":"Rader DJ","year":"2003","unstructured":"Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Investig. 2003, 6:1795-1803. 10.1172\/JCI200318925","journal-title":"J Clin Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs HH","year":"1992","unstructured":"Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992, 1:445-66. 10.1002\/humu.1380010602","journal-title":"Hum Mutat"},{"key":"ref12","article-title":"In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia","volume":"5","author":"Vega GL","year":"1986","unstructured":"Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Investig. 1986, 5:1410-4.","journal-title":"J Clin Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2006.110","article-title":"The proprotein convertases and their implication in sterol and\/or lipid metabolism","volume":"387","author":"Seidah NG","year":"2006","unstructured":"Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and\/or lipid metabolism. Biol Chem. 2006, 387:10.1515\/BC.2006.110","journal-title":"Biol Chem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000175431","article-title":"Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients","volume":"15","author":"Khachadurian AK","year":"1973","unstructured":"Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab. 1973, 15:132-40. 10.1159\/000175431","journal-title":"Nutr Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58111665","article-title":"Familial hypercholesterolemia and its current diagnostics and treatment possibilities: a literature analysis","volume":"58","author":"Zubielien\u0117 K","year":"2022","unstructured":"Zubielien\u0117 K, Valteryt\u0117 G, Jonaitien\u0117 N, \u017daliaduonyt\u0117 D, Zabiela V. Familial hypercholesterolemia and its current diagnostics and treatment possibilities: a literature analysis. Medicina (Kaunas). 2022, 58:1665. 10.3390\/medicina58111665","journal-title":"Medicina (Kaunas)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward NC","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019, 124:328-50. 10.1161\/CIRCRESAHA.118.312782","journal-title":"Circ Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(93)90260-2","article-title":"Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia","volume":"103","author":"Feher MD","year":"1993","unstructured":"Feher MD, Webb JC, Patel DD, Lant AF, Mayne PD, Knight BL, Soutar AK. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. Atherosclerosis. 1993, 103:171-80. 10.1016\/0021-9150(93)90260-2","journal-title":"Atherosclerosis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"2","author":"Raal FJ","year":"2000","unstructured":"Raal FJ, Pappu AS, Illingworth DR, et al.. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000, 2:421-8. 10.1016\/s0021-9150(99)00435-9","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"2","author":"Abifadel M","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, et al.. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Atherosclerosis. 2003, 2:154-6. 10.1038\/ng1161","journal-title":"Atherosclerosis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn M","year":"2010","unstructured":"Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010, 55:2833-42. 10.1016\/j.jacc.2010.02.044","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke ST","year":"2013","unstructured":"Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013, 76:269-76. 10.1111\/j.1365-2125.2012.04469.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(\u00ae)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary RS","year":"2015","unstructured":"Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(\u00ae)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet. 2015, 54:133-46. 10.1007\/s40262-014-0224-4","journal-title":"Clin Pharmacokinet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"375","author":"Raal FJ","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al.. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet. 2010, 375:998-1006. 10.1016\/S0140-6736(10)60284-X","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti C","year":"2017","unstructured":"Stefanutti C, Julius U, Watts GF, et al.. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017, 11:858-871.e3. 10.1016\/j.jacl.2017.04.114","journal-title":"J Clin Lipidol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080170017004","article-title":"Cholestyramine resin therapy for hypercholesterolemia: clinical and metabolic studies","volume":"192","author":"Hashim SA","year":"1965","unstructured":"Hashim SA, Vanitallie TB. Cholestyramine resin therapy for hypercholesterolemia: clinical and metabolic studies. JAMA. 1965, 192:289-93. 10.1001\/jama.1965.03080170017004","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright RS","year":"2021","unstructured":"Wright RS, Ray KK, Raal FJ, et al.. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021, 77:1182-93. 10.1016\/j.jacc.2020.12.058","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2021.0006","article-title":"Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia","volume":"30","author":"Surma S","year":"2023","unstructured":"Surma S, Roma\u0144czyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2023, 30:131-42. 10.5603\/CJ.a2021.0006","journal-title":"Cardiol J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13498","article-title":"A multi-purpose Japanese phase I study in the global development of vupanorsen: randomized, placebo-controlled, single-ascending dose study in adults","volume":"16","author":"Fukuhara K","year":"2023","unstructured":"Fukuhara K, Furihata K, Matsuoka N, et al.. A multi-purpose Japanese phase I study in the global development of vupanorsen: randomized, placebo-controlled, single-ascending dose study in adults. Clin Transl Sci. 2023, 16:886-97. 10.1111\/cts.13498","journal-title":"Clin Transl Sci"},{"key":"ref30","article-title":"Bempedoic acid (nexletol) for the treatment of hyperlipidemia and familial hypercholesterolemia","volume":"103","author":"Lawrence E","year":"2021","unstructured":"Lawrence E, Johns T. Bempedoic acid (nexletol) for the treatment of hyperlipidemia and familial hypercholesterolemia. Am Fam Physician. 2021, 103:377-8.","journal-title":"Am Fam Physician"},{"key":"ref31","unstructured":"A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1). (2020). Accessed. April 10, 2023: https:\/\/fdaaa.trialstracker.net\/trial\/NCT02722408\/."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia  (from the CLEAR Harmony Open-Label Extension Study)","volume":"174","author":"Ballantyne CM","year":"2022","unstructured":"Ballantyne CM, Banach M, Bays HE, et al.. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia  (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022, 174:1-11. 10.1016\/j.amjcard.2022.03.020","journal-title":"Am J Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36811","article-title":"A systematic review of the randomized controlled trials of gemcabene and its therapeutic uses","volume":"15","author":"Besekar SM","year":"2023","unstructured":"Besekar SM, Jogdand SD, Naqvi WM. A systematic review of the randomized controlled trials of gemcabene and its therapeutic uses. Cureus. 2023, 15:e36811. 10.7759\/cureus.36811","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24552","article-title":"The promising novel therapies for familial hypercholesterolemia","volume":"36","author":"Chen R","year":"2022","unstructured":"Chen R, Lin S, Chen X. The promising novel therapies for familial hypercholesterolemia. J Clin Lab Anal. 2022, 36:e24552. 10.1002\/jcla.24552","journal-title":"J Clin Lab Anal"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.07.005","article-title":"An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies","volume":"24","author":"McClorey G","year":"2015","unstructured":"McClorey G, Wood MJ. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol. 2015, 24:52-8. 10.1016\/j.coph.2015.07.005","journal-title":"Curr Opin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche JC","year":"2017","unstructured":"Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017, 3:17093. 10.1038\/nrdp.2017.93","journal-title":"Nat Rev Dis Primers"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/185978-familial-hypercholesterolemia-a-literature-review-of-the-pathophysiology-and-current-and-novel-treatments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:28Z","timestamp":1707508348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/185978-familial-hypercholesterolemia-a-literature-review-of-the-pathophysiology-and-current-and-novel-treatments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.49121","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}